Technical Analysis for CRVO - CervoMed Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | 0.08% | |
| Bollinger Band Squeeze | Range Contraction | 0.08% | |
| Earnings Movers | Other | 0.08% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.08% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 20 hours ago |
| Rose Above Upper Bollinger Band | about 20 hours ago |
| Up 3% | about 20 hours ago |
| Up 2% | about 20 hours ago |
| Up 1% | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Dermatology Oxygen Blastoma Macular Degeneration Glioblastoma Radiation Therapy Cancer Cell Signal Transduction Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris Pi3k/Akt/Mtor Pathway
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Dermatology Oxygen Blastoma Macular Degeneration Glioblastoma Radiation Therapy Cancer Cell Signal Transduction Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris Pi3k/Akt/Mtor Pathway
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.3789 |
| 52 Week Low | 4.14 |
| Average Volume | 23,245 |
| 200-Day Moving Average | 11.86 |
| 50-Day Moving Average | 22.54 |
| 20-Day Moving Average | 24.39 |
| 10-Day Moving Average | 24.38 |
| Average True Range | 1.62 |
| RSI (14) | 57.45 |
| ADX | 12.21 |
| +DI | 17.09 |
| -DI | 11.65 |
| Chandelier Exit (Long, 3 ATRs) | 20.82 |
| Chandelier Exit (Short, 3 ATRs) | 27.06 |
| Upper Bollinger Bands | 25.13 |
| Lower Bollinger Band | 23.65 |
| Percent B (%b) | 0.72 |
| BandWidth | 6.08 |
| MACD Line | 0.60 |
| MACD Signal Line | 0.76 |
| MACD Histogram | -0.1614 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.23 | ||||
| Resistance 3 (R3) | 27.26 | 26.47 | 26.81 | ||
| Resistance 2 (R2) | 26.47 | 25.83 | 26.45 | 26.67 | |
| Resistance 1 (R1) | 25.59 | 25.43 | 25.20 | 25.56 | 26.53 |
| Pivot Point | 24.80 | 24.80 | 24.60 | 24.78 | 24.80 |
| Support 1 (S1) | 23.92 | 24.16 | 23.53 | 23.89 | 22.91 |
| Support 2 (S2) | 23.13 | 23.76 | 23.11 | 22.77 | |
| Support 3 (S3) | 22.25 | 23.13 | 22.63 | ||
| Support 4 (S4) | 22.22 |
